-
Accenture Price Target Cut By This Analyst, Plus Deutsche Bank Predicts $483 For FactSet Research
Friday, September 23, 2022 - 8:14am | 422Credit Suisse cut FedEx Corporation (NYSE: FDX) price target from $246 to $236. FedEx shares fell 1.9% to $151.56 in pre-market trading. Deutsche Bank cut FactSet Research Systems Inc. (NYSE: FDS) price target from $507 to $483. FactSet Research shares fell 8.3% to close at $394.75 on Thursday...
-
Luna Innovations Shares Pop After New Contract With Medtech Giant Intuitive Surgical
Thursday, September 22, 2022 - 2:44pm | 316Luna Innovations Inc (NASDAQ: LUNA) announced a new $14.2 million contract with its long-standing partner Intuitive Surgical Inc (NASDAQ: ISRG). This new agreement provides for the supply of critical photonic subsystems manufactured by Luna and incorporated into Intuitive...
-
McKesson Buys Rx Savings Solutions For $875M
Monday, September 19, 2022 - 11:57am | 322McKesson Corp (NYSE: MCK) has agreed to acquire Rx Savings Solutions (RxSS), a prescription price transparency and benefit insight company offering affordability and adherence solutions to health plans and employers, reaching more than 17 million current patients. The...
-
Amazon, Target And 3 Other Stocks Insiders Are Selling
Monday, September 19, 2022 - 9:17am | 817U.S. crude oil futures traded lower this morning on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity...
-
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Thursday, September 1, 2022 - 6:36pm | 865The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ: NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares...
-
Neurocrine Biosciences Buys UK-Based Hormone Therapy Player
Tuesday, August 30, 2022 - 12:23pm | 254Neurocrine Biosciences Inc (NASDAQ: NBIX) has agreed to pay £48.3 million for the U.K. hormone therapy group, Diurnal Group Plc. The 27.5p share offered represents a 141% premium to last Friday's closing price. "Diurnal and Neurocrine are highly complementary...
-
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
Thursday, August 25, 2022 - 10:32am | 275Janssen Biotech Inc, a Johnson & Johnson (NYSE: JNJ) unit, received European conditional approval for Tecvayli (teclistamab) as monotherapy for relapsed or refractory multiple myeloma. Teclistamab is a T-cell redirecting bispecific antibody targeting both B-cell...
-
Tesla, Autodesk And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Thursday, August 25, 2022 - 6:07am | 399Snowflake Inc. (NYSE: SNOW) surged 17.4% to $187.18 in pre-market trading after the company reported better-than-expected Q2 sales results and issued product revenue guidance. FREYR Battery (NYSE: FREY) gained 14.7% to $12.14 in pre-market trading. FREYR Battery entered into strategic partnership...
-
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Wednesday, August 24, 2022 - 6:53pm | 648The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ: BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients....
-
Why Bed Bath & Beyond Is Trading Higher By 12%; Here Are 26 Stocks Moving Premarket
Wednesday, August 24, 2022 - 6:40am | 1055Gainers Bird Global, Inc. (NYSE: BRDS) shares rose 25.2% to $0.54 in pre-market trading. Bird secured permit extensions and expanded to new U.S. cities. Minerva Neurosciences, Inc. (NASDAQ: NERV) shares rose 20.4% to $5.43 in pre-market trading after Point72 Asset Management reported an 8.8%...
-
Netflix Price Target Cut By This Analyst, Plus Morgan Stanley Predicts $403 For McKesson
Monday, August 22, 2022 - 9:02am | 424UBS cut the price target for Coupa Software Incorporated (NASDAQ: COUP) from $84 to $76. Coupa Software shares fell 4.9% to $64.44 in pre-market trading. Morgan Stanley raised the price target on McKesson Corporation (NYSE: MCK) from $370 to $403. McKesson shares fell 0.3% to $369.99 in pre-...
-
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Friday, August 19, 2022 - 5:21pm | 417The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults. Axsome shares traded in a range of $50.5 to $61...
-
Cue Health's Molecular COVID-19 Test At Par With Lab Based PCR Tests
Thursday, August 18, 2022 - 7:06am | 367Cue Health Inc (NASDAQ: HLTH) announced the preprint publication of an independent clinical study demonstrating that its point of care (POC) molecular COVID-19 test is as accurate as a centralized lab-based RT-PCR. Cue's molecular test produces results in...
-
NOVN: EPI Revenue Trends Are Strong
Wednesday, August 17, 2022 - 7:52am | 2032By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT Second Quarter 2022 Results On August 11, 2022, Novan Inc. (NASDAQ: NOVN) reported second quarter financial and operational results in a press release and the filing of Form 10-Q. A conference call and webcast were...
-
Despite 36% Fall, Cue Health Q2 Revenues Exceed Expectations
Thursday, August 11, 2022 - 6:24am | 299Cue Health Inc (NASDAQ: HLTH) reported Q2 sales of $87.7 million, down 36% Y/Y, but exceeded guidance due to stronger than anticipated COVID-19 testing orders from existing customers. The analysts estimated sales of $52.90 million. Product revenues were $84.4 million compared to $...